These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

949 related articles for article (PubMed ID: 22066477)

  • 1. Similar clinical performance of a novel chimeric thyroid-stimulating hormone receptor bioassay and an automated thyroid-stimulating hormone receptor binding assay in Graves' disease.
    Kamijo K; Murayama H; Uzu T; Togashi K; Olivo PD; Kahaly GJ
    Thyroid; 2011 Dec; 21(12):1295-9. PubMed ID: 22066477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel bioreporter assay for thyrotropin receptor antibodies using a chimeric thyrotropin receptor (mc4) is more useful in differentiation of Graves' disease from painless thyroiditis than conventional thyrotropin-stimulating antibody assay using porcine thyroid cells.
    Kamijo K; Murayama H; Uzu T; Togashi K; Kahaly GJ
    Thyroid; 2010 Aug; 20(8):851-6. PubMed ID: 20615137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A TSHR-LH/CGR chimera that measures functional thyroid-stimulating autoantibodies (TSAb) can predict remission or recurrence in Graves' patients undergoing antithyroid drug (ATD) treatment.
    Giuliani C; Cerrone D; Harii N; Thornton M; Kohn LD; Dagia NM; Bucci I; Carpentieri M; Di Nenno B; Di Blasio A; Vitti P; Monaco F; Napolitano G
    J Clin Endocrinol Metab; 2012 Jul; 97(7):E1080-7. PubMed ID: 22492869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitive thyroid-stimulating antibody assay with high concentrations of polyethylene glycol for the diagnosis of Graves' disease.
    Takasu N; Kamijo K; Sato Y; Yoshimura H; Nagata A; Ochi Y
    Clin Exp Pharmacol Physiol; 2004; 31(5-6):314-9. PubMed ID: 15191404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A TSHr-LH/CGr chimera that measures functional TSAb in Graves' disease.
    Giuliani C; Cerrone D; Harii N; Thornton M; Kohn LD; Dagia NM; Fiore E; Bucci I; Chamblin T; Vitti P; Monaco F; Napolitano G
    J Clin Endocrinol Metab; 2012 Jul; 97(7):E1106-15. PubMed ID: 22496495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A bioluminescence assay for thyrotropin receptor antibodies predicts serum thyroid hormone levels in patients with de novo Graves' disease.
    Hovens GC; Buiting AM; Karperien M; Ballieux BE; van der Pluijm G; Pereira AM; Romijn JA; Smit JW
    Clin Endocrinol (Oxf); 2006 Apr; 64(4):429-35. PubMed ID: 16584516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stimulating and blocking thyroid-stimulating hormone (TSH) receptor autoantibodies from patients with Graves' disease and autoimmune hypothyroidism have very similar concentration, TSH receptor affinity, and binding sites.
    Morgenthaler NG; Ho SC; Minich WB
    J Clin Endocrinol Metab; 2007 Mar; 92(3):1058-65. PubMed ID: 17179194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding, stimulating and blocking TSH receptor antibodies to the thyrotropin receptor as predictors of relapse of Graves' disease after withdrawal of antithyroid treatment.
    Quadbeck B; Hoermann R; Hahn S; Roggenbuck U; Mann K; Janssen OE
    Horm Metab Res; 2005 Dec; 37(12):745-50. PubMed ID: 16372228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of a bioassay with CHO cells for the routine detection of stimulating and blocking autoantibodies to the TSH-receptor.
    Morgenthaler NG; Pampel I; Aust G; Seissler J; Scherbaum WA
    Horm Metab Res; 1998 Mar; 30(3):162-8. PubMed ID: 9566861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relevance of TSH receptor stimulating and blocking autoantibody measurement for the prediction of relapse in Graves' disease.
    Schott M; Minich WB; Willenberg HS; Papewalis C; Seissler J; Feldkamp J; Bergmann A; Scherbaum WA; Morgenthaler NG
    Horm Metab Res; 2005 Dec; 37(12):741-4. PubMed ID: 16372227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High cut-off value of a chimeric TSH receptor (Mc4)-based bioassay may improve prediction of relapse in Graves' disease for 12 months.
    Hwang S; Shin DY; Song MK; Lee EJ
    Endocrine; 2015 Feb; 48(1):89-95. PubMed ID: 24968734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of thyrotropin-receptor blocking antibodies on stimulating autoantibodies from patients with Graves' disease.
    Lenzner C; Morgenthaler NG
    Thyroid; 2003 Dec; 13(12):1153-61. PubMed ID: 14751037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of cells expressing the human thyrotropin (TSH) receptor for the measurement of thyroid stimulating and TSH-blocking antibodies.
    Vitti P; Chiovato L; Fiore E; Mammoli C; Rocchi R; Pinchera A
    Acta Med Austriaca; 1996; 23(1-2):52-6. PubMed ID: 8767515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thyrotrophin receptor antibody characteristics in a woman with long-standing Hashimoto's who developed Graves' disease and pretibial myxoedema.
    Kamath C; Young S; Kabelis K; Sanders J; Adlan MA; Furmaniak J; Rees Smith B; Premawardhana LD
    Clin Endocrinol (Oxf); 2012 Sep; 77(3):465-70. PubMed ID: 22891608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A rapid homogenous bioassay for detection of thyroid-stimulating antibodies based on a luminescent cyclic AMP biosensor.
    Miao LY; Kim HJ; Whitlatch K; Jaiswal D; Navarro A; Egan R; Olivo PD
    J Immunol Methods; 2022 Feb; 501():113199. PubMed ID: 34871593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of M22-based ELISA and human-TSH-receptor-based luminescence assay for the measurement of thyrotropin receptor antibodies in patients with thyroid diseases.
    Liu C; Hermsen D; Domberg J; Graeber C; Hautzel H; Duan Y; Xu KF; Liu CP; Mao XD; Cupisti K; Scherbaum WA; Schott M
    Horm Metab Res; 2008 Jul; 40(7):479-83. PubMed ID: 18504673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel hypothesis for the etiology of Graves' disease: TSAb may be thyroid stimulating animal IgG-like hormone and TBAb may be the precursor of TSAb.
    Ochi Y; Kajita Y; Hachiya T; Hamaoki M
    Med Hypotheses; 2012 Jun; 78(6):781-6. PubMed ID: 22472575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical value of the first automated TSH receptor autoantibody assay for the diagnosis of Graves' disease (GD): an international multicentre trial.
    Schott M; Hermsen D; Broecker-Preuss M; Casati M; Mas JC; Eckstein A; Gassner D; Golla R; Graeber C; van Helden J; Inomata K; Jarausch J; Kratzsch J; Miyazaki N; Moreno MA; Murakami T; Roth HJ; Stock W; Noh JY; Scherbaum WA; Mann K
    Clin Endocrinol (Oxf); 2009 Oct; 71(4):566-73. PubMed ID: 19170704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuously increasing sensitivity over three generations of TSH receptor autoantibody assays.
    Zöphel K; Roggenbuck D; Wunderlich G; Schott M
    Horm Metab Res; 2010 Nov; 42(12):900-2. PubMed ID: 20925015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of nonionic polymers on thyroid stimulation and TSH receptor binding by the human monoclonal TSH receptor autoantibody M22.
    Ochi Y; Hamazu M; Kajita Y; Hachiya T; Miyata T; Barrett C; Smith BR
    Thyroid; 2009 Jan; 19(1):47-52. PubMed ID: 18976151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.